Medicus Pharma Ltd (NASDAQ:MDCX) Receives $23.50 Consensus Target Price from Brokerages

Shares of Medicus Pharma Ltd (NASDAQ:MDCX) have received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $23.50.

A number of research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 22nd. Zacks Research raised Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $27.00 target price on shares of Medicus Pharma in a report on Monday, December 15th.

Medicus Pharma Stock Performance

Shares of NASDAQ:MDCX opened at $1.57 on Friday. The firm has a 50 day simple moving average of $2.09 and a 200 day simple moving average of $2.37. Medicus Pharma has a 52 week low of $1.49 and a 52 week high of $8.94. The company has a market cap of $34.48 million and a PE ratio of -0.73.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.27). On average, equities analysts predict that Medicus Pharma will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Medicus Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. May Hill Capital LLC purchased a new position in shares of Medicus Pharma during the 2nd quarter valued at $107,000. Guyasuta Investment Advisors Inc. acquired a new stake in Medicus Pharma during the second quarter valued at $230,000. Armistice Capital LLC acquired a new stake in Medicus Pharma during the first quarter valued at $4,710,000. SeaCrest Wealth Management LLC purchased a new position in Medicus Pharma in the second quarter valued at about $139,000. Finally, Brave Asset Management Inc. purchased a new stake in shares of Medicus Pharma during the 3rd quarter worth about $46,000.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.